H.C. Wainwright Upgrades Cassava Sciences(SAVA.US) to Buy Rating, Announces Target Price $116
Cassava Sciences Price Target Announced at $116.00/Share by HC Wainwright & Co.
Cassava Sciences Analyst Ratings
Cassava Sciences Upgraded to Buy From Neutral at H.C. Wainwright
Cassava Sciences Analyst Ratings
H.C. Wainwright Maintains Cassava Sciences(SAVA.US) With Hold Rating
JonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)
Cassava Sciences Analyst Ratings
Cassava Sciences Analyst Ratings
H.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)
Cassava Sciences Analyst Ratings
Cassava Sciences (SAVA) Was Downgraded to a Hold Rating at H.C. Wainwright
Analysts Offer Insights on Healthcare Companies: Aroa Biosurgery Ltd (AU:ARX), Cassava Sciences (SAVA) and Amplifon S.p.A. (GB:0N61)
Cassava Sciences Analyst Ratings
Cassava Sciences Progresses in Phase 3 Trials, Secures Strong Cash Position: A Buy Rating Justified
Cassava Sciences Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), CymaBay Therapeutics (CBAY)
Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)
Cassava Sciences' Simufilam Efficacy and Safety in Alzheimer's Treatment Bolsters Buy Rating: An Analysis of Trial Results and Future Projections